A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified.
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents of children with cancer use mental health services.
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
In 2024, an estimated 6 million pet dogs will be diagnosed with cancer in the United States. As someone who has lost several family dogs to cancer, I know how heartbreaking this diagnosis will be for each of those dogs’ owners.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
Over 18 million people are diagnosed with cancer in the United States and approximately 50% report clinical levels of depression and/or anxiety, pain, and/or fatigue.1-2
Developers of an investigational multi-target screening test for colorectal cancer and its precursors are aiming to replace the widely used conventional fecal immunochemical test.
I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”
In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
